Next-generation sequencing (NGS) tests encompassing multi-gene panels, whole-exome (WES), and whole-genome sequencing (WGS) are becoming an integral part of clinical diagnostics for hereditary cancers. However, analyzing and interpreting these panels can be incredibly time-consuming and complex.

Join Dr. Ana Krivokuca as she presents a use-case of how the Institute for Oncology and Radiology Serbia (IORS), a National Cancer Research Center, uses QCI Interpret, a clinical decision support software, in their NGS testing pipeline to annotate, assess, and interpret the clinical significance of germline variants in hereditary cancers.

Attendees will:

• Explore the challenges of variant classification, including the limitations of manual curation, handling of VUS, and incorporating guideline recommendations.
• Learn how the IORS uses QCI Interpret to evaluate genomic profiles of hereditary cancers and identify variants with clinical utility.
• Receive a demonstration of how QCI Interpret filters and prioritizes variants, transparently computes ACMG/AMP classifications, and auto-generates clinical reports with the latest evidence.